Method for alleviation of primary depressive disorders
CA 1313138 C · Owner: Bristol-Myers Squibb Company · Inventors: Cott, Jerry M.; Kurtz, Neil; Robinson, Donald S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Abstract of the Invention, Gepirone and its pharmaceutically acceptable salts are useful in alleviation of certain primary depressive disorders, such as major depression with melancholia and atypical depression. Method For Alleviation of Primary Depressive Disorders Field of the Invention, This invention is concerned with a drug bio-affecting body-treating process which employs the pyrimidine compound 4,4-dimethyl-1-4-4-(2-pyrimidinyl)-1-piperazinylbutyl-2 6-piperidinedione or a pharmaceutically acceptable acid addition salt thereof. -1-
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted January 26, 1993. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended January 26, 2010.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.